

APR 01 2005

SMART & BIGGAR


Intellectual Property & Technology Law


To Fax no.: (703) 872-9306 1000 De La Gauchetière Street West
Suite 3300
Page 1 of: 5 Montreal, Quebec Canada H3B 4W5
Attention: Jennifer I. HARLE, Examiner Tel. (514) 954-1500
USPTO Fax (514) 954-1396
From: S. Serge Shahinian
Your file no.: Application No. 09/885,914 **Date:** April 1, 2005
Filing Date: June 22, 2001
Reply to Montreal file no.: 85761-28 **Time:**

If there are any transmission problems, please call (514) 954-1500.

Original copy and any enclosures ☐ will be sent by ☒ mail
☒ will not ☒ courier

The information contained in this transmission is confidential and only for the intended recipient identified above. If you are not the intended recipient, you are hereby notified that any dissemination or use of this communication is unlawful. If you have received this transmission in error, please immediately notify us by telephone (collect). Return the original message to us and

| | | | |
|--|-------------------------------------|---------------------------------------|-------------------------------|
| CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) Applicant(s): DUBOIS, CLaire | | | Docket No. 85761-28 |
| Application No. 09/885,914 | Filing Date June 22, 2001 | Examiner HARLE, Jennifer L. | Group Art Unit 1654 |
| Invention: USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY OR MATRIX REMODELLING DISEASES | | | |
| <p>I hereby certify that this <u>RESPONSE TO RESTRICTION REQUIREMENT</u> <small>(Identify type of correspondence)</small></p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>(703) 872-9306</u>)</p> <p>on <u>April 1, 2005</u> <small>(Date)</small></p> <div style="text-align: right; margin-top: 20px;"> <u>Antoun Eid</u> <small>(Typed or Printed Name of Person Signing Certificate)</small>  <small>(Signature)</small> </div> <p style="text-align: center; margin-top: 40px;"> Note: Each paper must have its own certificate of mailing. </p> | | | |

| | | | | | |
|---|-------------------------------------|---------------------------------------|--|-------------------------------|---------------------------------|
| TRANSMITTAL LETTER (General - Patent Pending) | | | | | Docket No. 85761-28 |
| In Re Application Of: DUBOIS, Claire | | | | | |
| Application No. 09/885,914 | Filing Date June 22, 2001 | Examiner HARLE, Jennifer I. | Customer No. 28291 | Group Art Unit 1654 | Confirmation No. 5893 |
| Title: USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY OR MATRIX REMODELLING DISEASES | | | | | |
| <u>COMMISSIONER FOR PATENTS:</u> | | | | | |
| Transmitted herewith is: RESPONSE TO RESTRICTION REQUIREMENT | | | | | |
| in the above identified application. | | | | | |
| <input checked="" type="checkbox"/> No additional fee is required. | | | | | |
| <input type="checkbox"/> A check in the amount of _____ is attached. | | | | | |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 19-2530 as described below. | | | | | |
| <input type="checkbox"/> Charge the amount of _____ | | | | | |
| <input type="checkbox"/> Credit any overpayment. | | | | | |
| <input checked="" type="checkbox"/> Charge any additional fee required. | | | | | |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | | | | | |
| WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | |
|  Signature | | | Dated: April 1, 2005 | | |
| S. Serge Shahinian, Reg. No. 52,533 SMART & BIGGAR 1000 de la Gauchetiere Street West Suite 3300 Montreal, Quebec H3B 4W5 CANADA | | | <div>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date)</div> <div>_____ Signature of Person Mailing Correspondence</div> <div>_____ Typed or Printed Name of Person Mailing Correspondence</div> | | |
| cc: | | | | | |

RECEIVED
CENTRAL FAX CENTERPATENT
Docket No.: 85761-28

APR 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/885,914 Confirmation No. : 5893
Applicant : DUBOIS, Claire Art Unit : 1654
Filed : June 22, 2001
Title : USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS
IN THE TREATMENT OF INFLAMMATORY OR MATRIX
REMODELLING DISEASES

Examiner : Jennifer I. Harle

Docket No. 85761-28

Customer No. : 28291

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action dated March 3, 2005, Applicant hereby further elects "PDX", with traverse. The traversal is on the grounds set forth in Applicant's letter of December 22, 2004, that the Examiner has failed to establish that a search of the complete application would be an undue burden as required by MPEP 803. Therefore, it is requested that the entire application be searched and examined.

PATENT
Docket No.: 85761-28


In accordance with the above election with traverse, applicants reserve all rights in the non-elected claims, including the right to file one or more divisional applications covering the subject matter thereof.

Respectfully submitted,
SMART AND BIGGAR

April 1, 2005

Date

By



S. Serge Shahinian
Reg. No. 52,533
Tel.: (514) 954-1500

Please address correspondence to:
SMART & BIGGAR
1000 de la Gauchetière Street West
Suite 3300
Montreal, Quebec
H3B 4W5
CANADA